C07K 16/2839
Against the integrin superfamily
Official title: {against the integrin superfamily}
C07K16/2839 (Against the integrin superfamily) appears on 815 US grants and 1,415 published applications in this corpus.
Search patents in C07K- Granted patents
- 815
- Published applications
- 1,415
- Assignees
- 518
- Inventors
- 2,172
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 3 | 0 |
| 1992 | 5 | 0 |
| 1993 | 8 | 0 |
| 1994 | 9 | 0 |
| 1995 | 12 | 0 |
| 1996 | 10 | 0 |
| 1997 | 14 | 0 |
| 1998 | 29 | 0 |
| 1999 | 18 | 0 |
| 2000 | 16 | 0 |
| 2001 | 17 | 9 |
| 2002 | 9 | 32 |
| 2003 | 21 | 46 |
| 2004 | 12 | 53 |
| 2005 | 13 | 55 |
| 2006 | 14 | 42 |
| 2007 | 18 | 42 |
| 2008 | 27 | 38 |
| 2009 | 22 | 54 |
| 2010 | 28 | 68 |
| 2011 | 24 | 52 |
| 2012 | 25 | 53 |
| 2013 | 48 | 43 |
| 2014 | 31 | 58 |
| 2015 | 23 | 51 |
| 2016 | 27 | 68 |
| 2017 | 28 | 51 |
| 2018 | 42 | 71 |
| 2019 | 37 | 67 |
| 2020 | 33 | 73 |
| 2021 | 44 | 79 |
| 2022 | 29 | 58 |
| 2023 | 33 | 61 |
| 2024 | 30 | 73 |
| 2025 | 27 | 51 |
| 2026 | 24 | 67 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compositions and methods for treating cancer6 Oct 2026US 12,753,236 B2Alpha Beta Holdings, LLC
- Anti-VLA-4 antibodies15 Sep 2026US 12,734,236 B2Biogen MA Inc.
- Compositions for targeting muscle cells and uses thereof1 Sep 2026US 12,721,902 B2Cavalry Biosciences, Inc.
- Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels25 Aug 2026US 12,716,899 B2Biogen MA Inc.
- Method of treating inflammatory bowel disease11 Aug 2026US 12,703,749 B2Paragon Therapeutics, Inc.
- Methods of decreasing pathological neuroinflammation8 Oct 2026US 2026/0306585 A1Washington University
- Methods for treatment using anti-alpha4beta7 antibody8 Oct 2026US 2026/0306636 A1Takeda Pharmaceutical Company Limited
- Method of treating gastrointestinal inflammatory disease1 Oct 2026US 2026/0297197 A1Paragon Therapeutics, Inc.
- Compositions and methods involving integrin alpha3beta11 Oct 2026US 2026/0297198 A1149 Bio, LLC
- Antibodies targeting integrin beta-21 Oct 2026US 2026/0297199 A1
Most cited
By later US patents
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004
- Altered polypeptides with increased half-life795US 5,869,046 AGenentech, Inc. · 1999
- Antibody formulation655US 6,171,586 B2Genentech, Inc. · 2001
- Low pH hydrophobic interaction chromatography for antibody purification599US 5,641,870 AGenentech, Inc. · 1997
- Altered polypeptides with increased half-life489US 6,121,022 AGenentech, Inc. · 2000